Macro Group Pharmaceuticals - Macro Capital S.A.E results, Q4 2022
Net profit, assets, equity and cash flow for Q4 2022, against the same period a year earlier, from the published financial statements.
Net profit174 millionEGP · +17.5% vs the same period a year earlier
Total assets850 millionEGP · +47.2% vs the same period a year earlier
Shareholders' equity463 millionEGP · +29.3% vs the same period a year earlier
Operating cash flow135 millionEGP · +168.5% vs the same period a year earlier
In short
- Macro Group Pharmaceuticals - Macro Capital S.A.E's net profit for Q4 2022 was about 174 million EGP, up +17.5% from 148 million EGP in Q4 2021.
- Total assets at the end of Q4 2022 were about 850 million EGP, and shareholders' equity about 463 million EGP.
- Operating cash flow for Q4 2022 was positive at 135 million EGP.
Key lines against the same period a year earlier
This periodQ4 2021Change
Net profit174 million148 million+17.5%
Gross profit576 million480 million+19.9%
Total assets850 million577 million+47.2%
Total liabilities387 million219 million+76.4%
Shareholders' equity463 million358 million+29.3%
Total liabilities and equity850 million577 million+47.2%
Operating cash flow135 million50.26 million+168.5%
Investing cash flow-6.01 million-5.82 million−3.3%
Financing cash flow-2.5 million-44.15 million+94.3%
Net change in cash126 million291 thousand+43394.9%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Macro Group Pharmaceuticals - Macro Capital S.A.E's Q3 2026 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy